Study Results from Johns Hopkins University Bloomberg School of Public Health Provide New Insights into Managed Care and Specialty Pharmacy (Medicaid access to Most Favored Nation through the Pfizer agreement: The unanswered issues): Drugs and Therapies – Managed Care and Specialty Pharmacy

2026 MAY 13 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Current study results on Drugs and Therapies - Managed Care and Specialty Pharmacy have been published. According to news reporting originating in Baltimore, Maryland, by NewsRx journalists, research stated, “In the following commentary, we discuss the motivation for the Trump-Pfizer Most Favored Nation (MFN) pricing deal, a preliminary analysis on potential savings, and discussion on the details that will determine the success of the Trump-Pfizer deal. This deal represents the Trump administration’s pursued health policy to get Americans a ‘better deal’ for drug pricing by providing Medicaid programs access to MFN pricing for Pfizer-branded drugs.”

The news reporters obtained a quote from the research from the Johns Hopkins University Bloomberg School of Public Health, “Using different data sources, we provide a preliminary analysis on the deal’s impact on 6 Pfizer drugs. Our results suggest Medicaid programs may save a maximum of $280 million from access to MFN pricing, reflecting 11.5% in additional rebates off gross spending. Medicaid programs will have greater potential net savings when using MFN benchmarking for newer drugs with lower baseline rebates compared with older, highly rebated drugs. It is uncertain if the MFN prices will apply to all new and existing Pfizer drugs or just a selection.”

According to the news reporters, the research concluded: “We also highlight several implementation challenges ranging from different marketed names of drugs to selection of countries for MFN pricing that will influence the deal’s impact.”

This research has been peer-reviewed.

For more information on this research see: Medicaid access to Most Favored Nation through the Pfizer agreement: The unanswered issues. Journal of Managed Care & Specialty Pharmacy, 2026;32(5):525-529. Journal of Managed Care & Specialty Pharmacy can be contacted at: Acad Managed Care Pharmacy, 100 N Pitt St, 400, Alexandria, VA 22314-3134, USA.

Our news correspondents report that additional information may be obtained by contacting Joseph Levy, Dept. of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD. Additional authors for this research include Jeromie Ballreich, Tucker Desmond, Nathan Jibat and Gerard Anderson.

The publisher of the Journal of Managed Care & Specialty Pharmacy can be contacted at: Acad Managed Care Pharmacy, 100 N Pitt St, 400, Alexandria, VA 22314-3134, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)